Solid tumors (at any anatomic location, at any disease stage)
Conditions
Interventions
Group 1: Male and Female adult participants who are diagnosed with solid tumour cancers (at any anatomical location and at any stage of the disease) who have undergone an next-generation sequencing (N
Sponsors
F. Hoffmann-La Roche Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: The registry population will include adult patients who are diagnosed with solid tumor cancers (at any anatomical location) and at any stage of the disease. Both male and female patients will be included in this registry. Patients must meet the following criteria for enrolment in this registry: - Patient is an adult (according to age of majority as defined by local regulations) - Patient is currently diagnosed with any type of solid tumor cancer, at any stage of the disease, at the enrolment date (informed consent date) - Patient has undergone NGS testing, no longer than 3 months prior to the enrolment date, irrespective of the availability of test results - Informed consent has been obtained from the patient or legally authorized representative, as per local regulations
Exclusion criteria
Exclusion criteria: Patients who meet the below exclusion criterion at the time of enrolment will not be enrolled in this registry: - Patient has a prior or current diagnosis of hematological malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Registry objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research: Collect data that can inform future trial design and facilitate identification of potential trial populations; Provide a resource to identify, develop and qualify biomarkers, novel assessment tools and clinical endpoints; Provide a resource to support the conduct of disease-modeling studies 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes: Provide a resource to inform how precision medicine tools are used and how they affect patient care in the real world; Provide a resource to generate evidence that can support clinical, regulatory and access decision-making; Provide a resource to identify and assess clinical practices that can improve the healthcare of affected individuals 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing: Collect data that describes the history of patients undergoing NGS testing; Collect data that can help identify the complex genomic landscape affecting the diagnosis and prognosis of solid tumor cancers and deepen the understanding of underlying biologic pathways; Collect data that can help identify the sub-populations that may best benefit from precision medicine tools | — |
Secondary
| Measure | Time frame |
|---|---|
| This registry data will be shared with the medical and scientific community to foster research and support the generation of evidence. | — |
Countries
Argentina, Brazil, Canada, Colombia, Estonia, France, Germany, Ireland, Israel, Portugal, Spain, United Kingdom
Contacts
Public ContactErika Schirghuber
Roche Pharma AG
Outcome results
None listed